For the quarter ending 2025-09-30, IOVA had $25,686K increase in cash & cash equivalents over the period. -$89,546K in free cash flow.
| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net loss | -319,074 | - |
| Stock-based compensation expense | 11,900 | 37,858 |
| Unrealized foreign exchange loss | -232 | 97 |
| Amortization of intangible assets | 5,769 | 11,104 |
| Amortization of right of use asset | 2,922 | 5,747 |
| Depreciation and amortization of property and equipment | 2,986 | 6,152 |
| Deferred tax (benefit) expense | -2,405 | 150 |
| Excess and obsolescence reserve | 1,391 | 8,311 |
| Accretion of discounts and premiums on investments | 1,711 | 4,149 |
| Loss on asset disposals | 0 | -44 |
| Prepaid expenses, other assets and long-term assets | -2,776 | 10,138 |
| Trade accounts receivable | 6,823 | -9,402 |
| Inventory | 3,182 | 7,028 |
| Operating lease liabilities | -2,410 | -5,590 |
| Accounts payable | -4,393 | 2,945 |
| Accrued expenses and other liabilities | 5,499 | 1,969 |
| Net cash used in operating activities | -78,702 | -171,141 |
| Maturities of investments | 120,000 | 210,000 |
| Purchase of investments | 92,144 | 166,619 |
| Cash paid for acquisition, including contingent consideration, net of cash acquired | 0 | 0 |
| Purchase of property and equipment | 10,844 | 13,672 |
| Net cash provided by (used) in investing activities | 17,012 | 29,709 |
| Tax payments related to shares withheld for vested restricted stock units | 466 | 6,148 |
| Proceeds from the issuance of common stock under employee stock purchase plan | 2 | 669 |
| Proceeds from the issuance of common stock upon exercise of options | 0 | 15 |
| Proceeds from the issuance of common stock, net | 88,520 | 162,009 |
| Net cash provided by financing activities | 88,056 | 156,545 |
| Effect of foreign exchange rate changes | -680 | 1,247 |
| Net increase in cash, cash equivalents and restricted cash | 25,686 | 16,360 |
| Cash and cash equivalents at beginning of period | 122,053 | - |
| Cash and cash equivalents at end of period | 164,099 | - |
IOVANCE BIOTHERAPEUTICS, INC. (IOVA)
IOVANCE BIOTHERAPEUTICS, INC. (IOVA)